Jet Al Inc (JTAI): JTAI.......................................

Play Episode

6min

Proactive - Interviews for investors

Candel Therapeutics shares positive survival data for investigational immunotherapy in NSCLC

Candel Therapeutics CEO Dr. Paul Peter Tak joined Steve Darling from Proactive to announce final survival data from a Phase 2a clinical trial evaluating the company’s investigational immunotherapy in patients with stage III/IV non-small cell lung cancer (NSCLC) who had an inadequate response to immune checkpoint inhibitor (ICI) treatment. The study reported a median overall survival (mOS) of 24.5 months in 46 evaluable patients who received two courses of the investigational therapy. In a subset of patients who had progressive disease at baseline despite ICI treatment, mOS was 21.5 months. Historically, similar patients receiving standard-of-care chemotherapy have had mOS between 9.8 and 11.8 months, with published studies rarely exceeding 12 months. With a median follow-up of 32.4 months, the data demonstrated long-term survival benefits, with 37% of patients who had progressive disease despite ICI therapy still alive two years after treatment. Based on these positive results, Candel Therapeutics will continue advancing the development program, including preparations for a potential registrational trial in patients with non-squamous histology NSCLC. The U.S. Food and Drug Administration (FDA) has previously granted Fast Track Designation for the investigational therapy in combination with an antiviral agent and ICI therapy for patients with stage III/IV NSCLC who are resistant to first-line PD-(L)1 inhibitors and do not have activating molecular driver mutations or have progressed on targeted therapy. These findings support the therapy’s potential as a new treatment option for NSCLC patients with limited alternatives. #proactiveinvestors #candeltherapeuticsinc #nasdaq #cadl #CancerTreatment #ViralTherapy #ProstateCancer #PancreaticCancer #Glioblastoma #PaulPeterTak #ClinicalTrials #BiotechNews #Immunotherapy #Oncology #CancerResearch

Proactive - Interviews for investors

AuKing prepares for gold mining at Mt Freda site

AuKing Mining Ltd managing director Paul Williams talked with Proactive about the company's latest update on its Cloncurry Project in Queensland, focusing on the Mt Freda deposit. Williams confirmed that with Orion Resources nearing acquisition completion, AuKing is preparing to restart mining operations at the historical Mt Freda gold mine. Williams highlighted Mt Freda as a top target for redevelopment due to its existing mining lease and approvals, as well as a current resource estimate of around 100,000oz. "We really don't want to start a mining operation unless we've got reserves in the resource estimate," he explained, outlining the company’s aim to confirm and expand those figures through an upcoming drilling program. In addition to resource verification, AuKing is evaluating two processing options: existing vat leaching pits and a nearby cavern in-leach circuit at Lorena. Williams also noted the broader potential in the surrounding six square kilometre Mt Freda Complex, which contains multiple historical deposits, hinting at further exploration upside. Drilling is expected to start within weeks of the acquisition's financial close in April, with results anticipated in the months following. Williams described the program as "a fascinating exercise," indicating renewed momentum behind the restart strategy. For more updates from AuKing Mining Ltd and other resource sector insights, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe to the channel, and enable notifications for future content. #AuKingMining #MtFreda #GoldMining #ASXAKN #CloncurryProject #ResourceDrilling #MiningRestart #QueenslandMining #JuniorMining #GoldExploration #MiningInvestment #ASXResources #OrionResources

Proactive - Interviews for investors

Actinogen targets $20B Alzheimer’s market with Xanamem

Actinogen Medical Ltd Managing Director and CEO Dr Stephen Gourlay talked with Proactive at the AIM's Small and Midcap conference about the company’s lead asset, Xanamem, and its development in Alzheimer’s disease and depression. Dr Gourlay explained that Xanamem is an oral, once-a-day drug designed to modulate cortisol levels in the brain without interfering with the body’s essential stress response. “We’ve also shown some positive data, you know, phase two and depression as well, which is very exciting because that validates its mechanism,” he said. He outlined the commercial opportunity in both Alzheimer’s and depression. While depression is more prevalent, the Alzheimer's market offers larger potential revenue. He noted that current treatments either have side effects or provide only temporary cognitive improvement, whereas Xanamem could modify the disease course with a better safety profile. Dr Gourlay discussed Actinogen’s recent momentum, including positive results in a depression trial, a number of peer-reviewed publications, and the upcoming interim analysis from its Alzheimer’s trial in Australia and the US. He said, “The upside from a positive Alzheimer’s trial is completely massive… a multi-billion dollar asset.” The company is currently trading below the total investment into drug development, which Dr Gourlay described as a compelling investment case. #Actinogen #Xanamem #AlzheimersResearch #DepressionTreatment #BiotechStocks #ClinicalTrials #Neuroscience #PharmaInnovation #ASX #ProactiveInvestors

Proactive - Interviews for investors

Fineqia International CEO unveils first DeFi yield ETP

Fineqia International Inc (CSE:FNQ, OTC:FNQQF) CEO Bundeep Singh Rangar talked with Proactive's Stephen Gunnion about launching the world’s first exchange-traded product (ETP) that deploys digital assets in yield-bearing decentralized finance (DeFi). Rangar explained the product's unique value, providing access to DeFi yield through a transparent, regulated security listed on the Vienna Stock Exchange. The Fineqia FTSE Cardano Enhanced Yield ETN (AV:YADA) is based on the Cardano network, a top ten cryptocurrency valued at over $35 billion, and allows investors to participate in DeFi activities such as borrowing, lending, and validating transactions, which generate fees. Unlike traditional ETFs and ETNs, Fineqia's product reinvests 80% of these yields back to investors, making it a truly innovative approach. Rangar highlighted the importance of partnering with FTSE Russell, a subsidiary of the London Stock Exchange, to ensure robust pricing data for this groundbreaking product. He added, "This is an icebreaker for what we want to do in the industry... We’re about being innovative and different." This collaboration sets a milestone for the ETP industry by combining blockchain technology and traditional finance, giving fund managers and retail investors easy access to decentralized finance through a familiar financial instrument. Visit Proactive's YouTube channel for more videos like this one, and don’t forget to give the video a like, subscribe to the channel, and enable notifications for updates! #Fineqia #DeFi #CryptoETP #DecentralizedFinance #Cardano #DigitalAssets #ETN #CryptoInvesting #Blockchain #FTSERussell

Followers	248
Posts	44148
Boards Moderated	0
Alias Born	12/05/2003

Volume:	34,918
Day Range:	3.9027 - 4.1512
Bid:	3.91
Ask:	3.95
Last Trade Time:	11:03:25 AM EDT
Total Trades:	458

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

JTAI Detailed Quote

Recent JTAI News

More JTAI News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent JTAI News

Go Ad-Free